Navigation Links
Lilly Reports First-Quarter 2011 Results
Date:4/18/2011

$1.13(16)%In-process research and development charges

  associated with Boehringer Ingelheim

  collaboration (2011) and Acrux licensing

  agreement (2010).23.03Asset impairments and restructuring charges

.06.02Earnings per share (non-GAAP)  $1.24$1.185%U.S. Health Care Reform Impact

U.S. health care reform reduced first-quarters 2011 and 2010 earnings per share by approximately $.10 and $.12 per share, respectively, on both a reported and non-GAAP basis. For the first quarter of 2011, U.S. health care reform reduced revenue by approximately $90 million due to higher rebates and subsidies, and increased administrative expenses by approximately $45 million related to the mandatory pharmaceutical manufacturers fee. For the first quarter of 2010, U.S. health care reform reduced revenue by approximately $60 million due to higher rebates, and increased tax expense by $85.1 million due to the imposition of tax on the prescription drug subsidy of the company's retiree health plan.(Dollars in millions)First Quarter

% Change

Over/(Under)20112010

2010Zyprexa

$1,281.9$1,215.06%Cymbalta®

908.8803.213%Alimta®

579.9527.410%Humalog®

525.4506.44%Cialis®

434.4408.36%Humulin®

289.8257.812%Evista®

266.1241.610%Forteo®

216.1194.511%Gemzar®

156.1287.8(46)%Strattera®

138.7146.4(5)%Animal Health

369.8289.628%Total Revenue

$5,839.2$5,485.56%Zyprexa

In the first quarter of 2011, Zyprexa sales totaled $1.282 billion, an increase of 6 percent compared with the first quarter of 2010.  U.S. sales of Zyprexa increased 2 percent to $597.1 million, driven by higher prices, partially offset by lower volume. Zyprexa sales in international markets increased 8 percent, to $684.8 million, driven primarily by higher volume, and to a lesser extent the favorable impact of foreign exchang
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
(Date:7/31/2015)... 2015 Today, the National Association of ... issued a report urging greater accountability by the ... against websites illegally selling medications online. As detailed ... Program Progress Report for State and Federal Regulators: ... websites illegally distribute medications and avoid retribution. Such ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3
... June 8, 2011 ForteBio®, Inc., a leading ... of biotherapeutic and pharmaceutical products, today announced the ... Fc Capture (AMC) biosensor for use on the ... high-throughput rapid kinetic characterization and screening of mouse ...
... 8, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical company developing ... today announced the appointment of Mr. Jonathan B. Lloyd ... president of corporate development. Mr. Lloyd ... development and finance experience.  He has led negotiations, valuation ...
Cached Medicine Technology:ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies 2TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development 2
(Date:8/3/2015)... ... 2015 , ... Novatus, Inc. today launched the largest and ... as announced the date of its next major release. , Version 6.0 introduces ... as well as enhancements to the customer experience. Users now enjoy a ...
(Date:8/3/2015)... ... 03, 2015 , ... Results of a comprehensive survey by ... and Policy Analysis show widespread support for the U.S. Affordable Care Act among ... agreed that the controversial law passed in 2010 had “more good than bad” ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... ... A July 13 article from The Daily Mail titled "Jab That ... Can Last 'For Five Weeks'" discusses the use of stem cells to help ... harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal cells ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... , To The Editor: Recent deaths ... bacterial,infections in shellfish should remind people with certain ... shellfish,particularly during warm weather when waters in the ... of Vibrio vulnificus bacteria., Vibrio vulnificus is ...
... 15 Young Innovations, Inc.,(Nasdaq: YDNT ) today ... with a live and on-demand web cast conference call ... live audio broadcast of the,call will be available through ... broadcast will also be available through the,Company,s website, ...
... PARK, Calif., Oct. 15 Exponent, Inc.,(Nasdaq: EXPO ... ended,September 26, 2008., For the third quarter of ... $48,904,000, in the same period of 2007.,Revenues before reimbursements ... Net income was up 18% to $5,942,000, or $0.38 ...
... Hospice Pediatric Patients, WASHINGTON, Oct. 15 ... (USAID) and funding from the U.S.,President,s Emergency Plan ... has developed one of South Africa,s first children,s ... by youngsters with,life-threatening illnesses, including AIDS and cancer., ...
... University and Delta Dental Foundation project is working to ... of thousands of Indiana children, INDIANAPOLIS, Oct. 15 ... between January and September 2008 by an,Indiana University School of ... Indiana, a mobile dental sealant program operated by the,university and ...
... mathematician who has applied mathematical modeling techniques to elucidate the ... methods to ascertain the players most deserving of major league ... awards. Bukiet, a popular NJIT math professor, dives annually ... game, but also for his love of teaching and math. ...
Cached Medicine News:Health News:Important Health Issue From Be Oyster Aware 2Health News:Young Innovations, Inc. Provides Third Quarter Conference Call Details 2Health News:Exponent Reports Third Quarter 2008 Results 2Health News:Exponent Reports Third Quarter 2008 Results 3Health News:Exponent Reports Third Quarter 2008 Results 4Health News:Exponent Reports Third Quarter 2008 Results 5Health News:Exponent Reports Third Quarter 2008 Results 6Health News:Exponent Reports Third Quarter 2008 Results 7Health News:Exponent Reports Third Quarter 2008 Results 8Health News:Children with Life-Threatening Illnesses Receive Hospice Care 2Health News:SEAL Indiana Reports More Than Half of Indianapolis Area School Kids Treated by Program Have Moderate or Severe Dental Decay 2Health News:Using math model, NJIT professor names MVP and Cy Young award contenders 2Health News:Using math model, NJIT professor names MVP and Cy Young award contenders 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: